China's medical products administrator approved Innovent Biologics' (HKG:1801) limertinib for a mutation of locally advanced or metastatic non-small cell lung cancer, according to a Friday filing with the Hong Kong Exchange.
The drug is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
It is indicated for the EGFR T790M mutation, which is the most common mutation and affects up to 50% of Asian patients of the disease, the filing said.
Shares rose 3% during Friday's late morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.